Literature DB >> 19307525

The value of family history as a risk indicator for venous thrombosis.

Irene D Bezemer1, Felix J M van der Meer, Jeroen C J Eikenboom, Frits R Rosendaal, Carine J M Doggen.   

Abstract

BACKGROUND: A positive family history of venous thrombosis may reflect the presence of genetic risk factors. Once a risk factor has been identified, it is not known whether family history is of additional value in predicting an individual's risk. We studied the contribution of family history to the risk of venous thrombosis in relation to known risk factors.
METHODS: In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis, a population-based case-control study, we collected blood samples and information about family history and environmental triggers from 1605 patients with a first venous thrombosis and 2159 control subjects.
RESULTS: A total of 505 patients (31.5%) and 373 controls (17.3%) reported having 1 or more first-degree relatives with a history of venous thrombosis. A positive family history increased the risk of venous thrombosis more than 2-fold (odds ratio [95% confidence interval], 2.2 [1.9-2.6]) and up to 4-fold (3.9 [2.7-5.7]) when more than 1 relative was affected. Family history corresponded poorly with known genetic risk factors. Both in those with and without genetic or environmental risk factors, family history remained associated with venous thrombosis. The risk increased with the number of factors identified; for those with a genetic and environmental risk factor and a positive family history, the risk was about 64-fold higher than for those with no known risk factor and a negative family history.
CONCLUSIONS: Family history is a risk indicator for a first venous thrombosis, regardless of the other risk factors identified. In clinical practice, family history may be more useful for risk assessment than thrombophilia testing.

Entities:  

Mesh:

Year:  2009        PMID: 19307525     DOI: 10.1001/archinternmed.2008.589

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  44 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Thrombophilia: clinical-practical aspects.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Usefulness of factor V Leiden mutation testing in clinical practice.

Authors:  Ellen Ø Blinkenberg; Ann-Helen Kristoffersen; Sverre Sandberg; Vidar M Steen; Gunnar Houge
Journal:  Eur J Hum Genet       Date:  2010-03-24       Impact factor: 4.246

Review 4.  Role of thrombophilia testing: con.

Authors:  Scott M Stevens
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 5.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

6.  Taller height as a risk factor for venous thromboembolism: a Mendelian randomization meta-analysis.

Authors:  N S Roetker; S M Armasu; J S Pankow; P L Lutsey; W Tang; M A Rosenberg; T M Palmer; R F MacLehose; S R Heckbert; M Cushman; M de Andrade; A R Folsom
Journal:  J Thromb Haemost       Date:  2017-06-06       Impact factor: 5.824

7.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

8.  Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study.

Authors:  S Y Kristinsson; L Goldin; I Turesson; M Hultcrantz; M Björkholm; O Landgren
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

Review 9.  Progress in the research on venous thromboembolism.

Authors:  Zhen Zhang; Liang Tang; Yu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

10.  Thrombin generation profile in non-thrombotic factor V Leiden carriers.

Authors:  Paul Billoir; Thomas Duflot; Marielle Fresel; Marie Hélène Chrétien; Virginie Barbay; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.